Anticancer Bioscience is a growing precision therapeutics company headquartered in Chengdu, China, with global research and development teams in India, the United Kingdom, and the United States. The company is dedicated to the development of synthetic lethal therapies that address unmet medical needs.

1. Anticancer Bioscience
A Precision Therapeutics Company
Dedicated to Synthetic Lethal Therapies
Anticancer Bioscience © 2020

2. Our mission is to provide clinical
benefits to millions of cancer
patients worldwide
2
Anticancer Bioscience © 2020

3. Our Locations
Chengdu, China
R&D Headquarters
Hyderabad, India
Medicinal Chemistry
St Andrews, UK
Bioinformatics and
Biostatistics
San Francisco, US
Preclinical Studies
IP Portfolio Management
Business Development
anticancerbio.com
3

4. Technology Platforms
Centrosome
Targeting
Tumor Suppressor
Synthetic Lethality
Restoration of
Contact Inhibition
Polyploid Cell
Synthetic Lethality
Oncogene Enabled
Synthetic Lethality
Natural Product
Libraries
Small Molecule
Libraries
• We pursue knowledge-based approaches to the
discovery, design and development of novel small
molecule therapeutics
• Our synthetic lethal screens derive novel bioactive leads
• Biomarker-driven programs so the patient gets a
matching therapeutic for their cancer
• Novel mechanisms of action that are amenable to
combination therapy
anticancerbio.com
4

5. Synthetic Lethality
• Cancer progresses through a series of genetic and
epigenetic changes that fuel carcinogenesis
• Synthetic lethality is possible when the same genetic
changes that enable carcinogenesis also make the
cancer cell overly dependent on specific pathways and
proteins
• Attacking these dependencies with drugs can yield
dramatic anti-cancer effects, while leaving normal cells
healthy
• Synthetic lethality enables targeting of drivers of
carcinogenesis that are not currently amenable to drug
development
anticancerbio.com
5

6. Natural Product Drug Discovery
Nature Produces Chemical Diversity
• Natural products are rich sources of chemical diversity
• Empirical experiences related to the use of botanical
medicines (Ethnopharmacology) can inform the
discovery process
• Examples of chemotherapeutics derived from plants
include taxol (bark of Taxus brevifolia) and vinca
alkaloids (periwinkle plant Catharanthus roseus)
Natural Resources
Crude Extract Library
Prefractionated Library
Pure Natural Compound Library
Diversity Enhanced Library
Bioactive
Screening
Active Phytochemicals
anticancerbio.com
6

7. Natural Product Drug Discovery
Natural Product Drug Discovery Platform
• We have assembled over 20,000 natural product
extracts, over 1,000 partial purified natural product
fractions, and over 2,000 pure natural compounds
• We have successfully screened, isolated and
identified bioactive components that are synthetic
lethal with a variety of cancer-associated genomic
changes and polyploidy
• Phytochemicals can start as building blocks for the
synthesis of more potent and bioavailable
derivatives
Natural Resources
Crude Extract Library
Prefractionated Library
Pure Natural Compound Library
Diversity Enhanced Library
Bioactive
Screening
Active Phytochemicals
anticancerbio.com
7

8. Small Molecule Drug Discovery
Small molecule drugs
• Small molecule drugs are low molecular weight (<900 Dalton) organic
compounds that can regulate a biological process by binding specific
macromolecules, such as proteins
• Novel screening bioassays are required to unlock unknown biologic
function and optimize the relationship between small molecule structure
and activity
• Advantages inherent to small molecule drugs are that they can cross cell
membranes to inhibit intracellular targets, can be designed to interact
with kinase binding pockets and often can be made orally bioavailable
NCEa
Library
Development
Bioactive
Screeningb
Structure-
Activity Analysis
Lead
Identification
Optimization
Drug Candidate
a
NCE: New Chemical Entity
b
NCE and Natural Product screens
anticancerbio.com
8

9. Small Molecule Drug Discovery
Small Molecule Drug Discovery Platform
• We develop drugs, from hit-to-lead and beyond, using small molecule
libraries and bioactive phytochemicals from natural product libraries
• Our library design and synthesis focuses on creation of New Chemical
Entity (NCE) libraries so as to derive novel lead-like molecules
• We integrate methods in medicinal chemistry, molecular modeling
through target and fragment-based drug discovery and bioassay-driven
structure-activity analysis for lead generation and in-house molecular
optimization
NCEa
Library
Development
Bioactive
Screeningb
Structure-
Activity Analysis
Lead
Identification
Optimization
Drug Candidate
a
NCE: New Chemical Entity
b
NCE and Natural Product screens
anticancerbio.com
9

10. Our Pipeline
Oncogenic
Alterations
Targets
Basic
Research
Hits
Discovery
Hits to
Leads
Lead
Optimization
Preclinical
Studies
Upcoming
Milestones
Rights
Oncogene Enabled SL Drugs
MYChigh Undisclosed
File IND in
Q4 2021
Polyploid Cell SL Drugs
Polyploidy Undisclosed
Initiate
IND-enabling
Studies in
Q2 2021
Tumor Suppressor SL Drugs
p53-deficiency
Validation
Stage
Complete Lead
Optimization
Centrosome Targeting Drugs
Centrosome
Amplification
Undisclosed
Initiate
IND-enabling
Studies in
Q1 2021
Contact Inhibition (CI) Restoration Drugs
Loss of CI Undisclosed
Phase I / II
Trials in
Q3 2021
anticancerbio.com
10

11. Our Partners
We partner with Goodwin Proctor LLP, a
Global 50 law firm, for our patent portfolio
managements.
We partner with J. Michael Bishop Institute of
Cancer Research, who strives to harness
advanced technologies to increase the
understanding of cancer cell biology.
anticancerbio.com
11

12. Contact Us
www.anticancerbio.com
General Inquiries:
info@anticancerbio.com
Partnerships & Business Development:
bd@anticancerbio.com
Follow us: @ACBsci
D6, Chengdu Tianfu International Bio-Town
anticancerbio.com
12

13. anticancerbio.com